Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN-725 in advanced solid tumors
NCT07229898Phase 1Recruiting
- Sponsor
- Genuine Biotech
- Start
- Jan 2025
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azvudine in solid tumor (advanced stage), sponsored by Genuine Biotech. Primary endpoints: Dose-Limiting Toxicity at Day 25, Adverse Events and 1 more. Started Jan 2025; status: recruiting.
02
Drugs
azvudine
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT07229898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07229898.